Reference : Hyperammonemia after high-dose chemotherapy and stem cell transplantation.
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/9448
Hyperammonemia after high-dose chemotherapy and stem cell transplantation.
English
Frere, Pascale mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Canivet, Jean-Luc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Soins intensifs >]
Gennigens, Christine mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Rebeix, J. P. [> > > >]
Fillet, Georges mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Beguin, Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
2000
Bone Marrow Transplantation
Nature Publishing Group
26
3
343-5
Yes (verified by ORBi)
International
0268-3369
London
United Kingdom
[en] Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/therapeutic use ; Cyclophosphamide/administration & dosage/adverse effects ; Dexamethasone/administration & dosage/adverse effects ; Doxorubicin/administration & dosage/adverse effects ; Female ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Hyperammonemia/etiology ; Melphalan/administration & dosage/adverse effects ; Middle Aged ; Multiple Myeloma/blood/drug therapy/therapy ; Prednisolone/administration & dosage/adverse effects ; Vincristine/administration & dosage/adverse effects
[en] We report a patient with multiple myeloma who suffered from hyperammonemia after a second stem cell autograft. This syndrome is not well known but is associated with a high mortality rate. Considering the possibility of this diagnosis in patients developing confusion and neurological degradation with respiratory alkalosis after intensive chemotherapy, could allow earlier treatment and perhaps improved survival. Possible mechanisms and potential therapies are discussed. With rapid recognition and treatment of the syndrome, the patient fully recovered. One and a half years later, she is still alive and well, on interferon for persisting myeloma.
http://hdl.handle.net/2268/9448
10.1038/sj.bmt.1702485

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
129.pdfPublisher postprint42.31 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.